Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics


Evelo Biosciences, Inc. (EVLO): $0.25

-0.01 (-3.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVLO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

EVLO Stock Price Chart Interactive Chart >

Price chart for EVLO

EVLO Price/Volume Stats

Current price $0.25 52-week high $4.36
Prev. close $0.26 52-week low $0.24
Day low $0.24 Volume 162,955
Day high $0.28 Avg. volume 165,289
50-day MA $0.83 Dividend yield N/A
200-day MA $1.80 Market Cap 27.00M

Evelo Biosciences, Inc. (EVLO) Company Bio


Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.


EVLO Latest News Stream


Event/Time News Detail
Loading, please wait...

EVLO Latest Social Stream


Loading social stream, please wait...

View Full EVLO Social Stream

Latest EVLO News From Around the Web

Below are the latest news stories about EVELO BIOSCIENCES INC that investors may wish to consider to help them evaluate EVLO as an investment opportunity.

Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the fourth quarter and full year 2022. “We continued to progress on our SINTAX platform and our clinical pipeline in 2022. We look forward to important cl

Yahoo | March 16, 2023

Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial results and business highlights. To listen to the conference call by ph

Yahoo | March 9, 2023

After Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences, Inc. (EVLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | March 1, 2023

Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, today announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET. A live audio webcast of the panel will be available

Yahoo | March 1, 2023

Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial

– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated – – EDP2939 Phase 2 data in psoriasis anticipated in 2H 2023 – CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intesti

Yahoo | February 27, 2023

Read More 'EVLO' Stories Here

EVLO Price Returns

1-mo -69.66%
3-mo -82.88%
6-mo -87.56%
1-year -93.13%
3-year -92.69%
5-year N/A
YTD -84.47%
2022 -73.48%
2021 -49.79%
2020 197.78%
2019 -68.79%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7182 seconds.